All In Biotech

NDA 020468 · Chattem Sanofi

Nasacort Allergy 24 Hour

Triamcinolone Acetonide · Nasal · Corticosteroid

Priority review

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 20, 1996

Approved uses

6

Original approval plus efficacy supplements

Registered trials

692

135 Phase 3, 52 recruiting

FAERS reports

29,292

13,599 serious, 3,180 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 14, 2026.

Uses temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion runny nose sneezing itchy nose

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NASACORT ALLERGY 24 HOUR · TRIAMCINOLONE ACETONIDE 0.055MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Triamcinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 692 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,253
  • off label use2,925
  • pruritus2,760
  • rash2,607
  • pain2,187
  • fatigue2,113
  • nausea2,038
  • headache1,872
  • condition aggravated1,798
  • diarrhoea1,763
  • product use in unapproved indication1,763
  • vomiting1,741

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200471
200558
200640
200780
2008116
2009110
2010113
2011177
2012175
2013203
2014253
20152,003
20161,396
20171,355
20181,687
20191,455
20201,650
20211,913
20222,445
20232,871
20243,654
20254,065
20263,402

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 990 on PubMed

Sponsor: Chattem Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.